AZD0095 is a selective and orally active MCT4 inhibitor (IC 50 : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205).
性状
Solid
IC50 & Target[1][2]
MCT4 1.3 nM (IC50)
体外研究(In Vitro)
AZD0095 (0-50 μM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖,IC50 为 26 nM。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
AZD0095 (100 mg/kg, 口服,一天两次) 与 Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Murine NCI-H358 xenograft
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
参考文献
[1]. Goldberg FW, et al. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem. 2022 Dec 16.